Galmed Pharmaceuticals (GLMD) Assets Average (2014 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Assets Average of $17.3 million for Q1 2026, up 77.35% year-over-year from $9.8 million in Q1 2025, and down 13.82% quarter-over-quarter from $20.1 million in Q4 2025.
Galmed Pharmaceuticals (GLMD) Assets Average (2014 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Assets Average history runs 13 years deep, the most recent figure standing at $17.3 million for Q1 2026.
- In Q1 2026, Assets Average rose 77.35% year-over-year to $17.3 million; the TTM figure through Mar 2026 stood at $17.3 million (up 77.35% YoY), while the FY2025 annual figure was $9.7 million, up 11.43% from the prior year.
- Assets Average for Q1 2026 stood at $17.3 million, down from $20.1 million in the prior quarter.
- The five-year high for Assets Average was $33.4 million in Q1 2022, with the low at $7.2 million in Q2 2023.
- The 5-year median for Assets Average is $17.1 million (2024), against an average of $17.5 million.
- The sharpest annual moves came in 2023 and 2024: Assets Average slumped 73.42% in 2023, then jumped 92.54% in 2024.
- Galmed Pharmaceuticals' Assets Average stood at $18.7 million in 2022, then declined by 8.45% to $17.1 million in 2023, then plunged by 36.36% to $10.9 million in 2024, then surged by 84.4% to $20.1 million in 2025, then slipped by 13.82% to $17.3 million in 2026.
- Business Quant data shows GLMD's Assets Average at $17.3 million in Q1 2026, $20.1 million in Q4 2025, and $22.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Galmed Pharmaceuticals | 2.39 Mn | -9.49 Mn | - | 17.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.33 Mn |
| Dec 31, 2025 | 20.11 Mn |
| Sep 30, 2025 | 22.26 Mn |
| Jun 30, 2025 | 20.81 Mn |
| Mar 31, 2025 | 9.77 Mn |
| Dec 31, 2024 | 10.90 Mn |
| Sep 30, 2024 | 17.15 Mn |
| Jun 30, 2024 | 13.93 Mn |
| Mar 31, 2024 | 15.58 Mn |
| Dec 31, 2023 | 17.13 Mn |
| Sep 30, 2023 | 15.46 Mn |
| Jun 30, 2023 | 7.24 Mn |
| Mar 31, 2023 | 8.88 Mn |
| Dec 31, 2022 | 18.72 Mn |
| Sep 30, 2022 | 22.22 Mn |
| Jun 30, 2022 | 26.89 Mn |
| Mar 31, 2022 | 33.40 Mn |
| Dec 31, 2021 | 40.45 Mn |
| Sep 30, 2021 | 48.31 Mn |
| Jun 30, 2021 | 56.35 Mn |